Eiki Igarashi is CEO of Nanosion Co., Ltd., a nanobioventure company in Tokyo, Japan. He is also a guest investigator at the National Institute of Advanced Industrial Science and Technology, Tokyo, Japan, where he collects and reviews medical information regarding the practical application, toxicology, and pharmacokinetics of nanoproducts and nanomaterials, ranging from metallic nanoparticles and carbon nanotubes to nanomedicines, nanofoods, nanocosmeceuticals, and nanoconsumer products. He holds a doctoral degree from Hiroshima University, Japan, and has worked in various capacities with Marion Merrell Dow Co., Ltd. (the pharmaceutical company of the Dow Chemical Company), Hirakata, Japan; Kyoto University, Japan; and Hoechst Marion Roussel Co., Ltd., Tokyo, Japan.
